Prothena Corp Plc (PRTA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Prothena Corp Plc (PRTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8271
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:63
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Prothena Corp Plc (Prothena) is a clinical biotechnology company, which discovers, develops and markets novel medicines that are indicated for the treatment of diseases associated with neuroscience and orphan diseases. The company develops monoclonal antibodies directed specifically at disease-causing proteins. Its pipeline products include PRX002, that targets alpha -synuclein protein for the treatment of Parkinson’s disease and other synucleinopathies; NEOD001, that targets the circulating soluble and deposited aggregated amyloid in the treatment of primary systemic amyloidosis; PRX004, indicated to clear the misfolded (toxic) forms of the TTR amyloid protein in Transthyretin amyloidosis (ATTR amyloidosis). Protena also develops several discovery-stage programs in collaboration with other pharmaceurtical companies for neurodegenerative or orphan diseases such as Alzheimer’s disease (AD), ALECT2 amyloidosis, frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Prothena is headquartered in Dublin, Ireland.

Prothena Corp Plc (PRTA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Prothena Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Prothena Corp Plc, Medical Devices Deals, 2012 to YTD 2018 10
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Prothena Biosciences Enters into R&D Agreement with Celgene Switzerland 12
MJFF Enters into Agreement with Prothena 14
Licensing Agreements 15
Roche Enters Into Licensing Agreement With Prothena 15
Equity Offering 17
Prothena Files Registration Statement for Public Offering of Shares 17
Prothena Raises USD155.3 Million in Public Offering of Shares 18
Prothena Raises USD137 Million in Public Offering of Shares 20
Prothena Raises USD122 Million in Public Offering of Shares 22
Prothena Completes Exercise of Underwriter’s Over Allotment Option for Public Offering of Shares for USD123 Million 24
Prothena Raises USD82.7 Million in Public Offering of Shares 26
Prothena Completes Public Offering Of Shares For US$92 Million 28
Prothena Corp Plc – Key Competitors 30
Prothena Corp Plc – Key Employees 31
Prothena Corp Plc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Recent Developments 33
Strategy And Business Planning 33
May 24, 2018: Prothena Announces Reorganization to Focus Resources on Advancing Neuroscience Pipeline 33
Financial Announcements 34
Aug 07, 2018: Prothena reports second quarter 2018 financial results and provides R&D update 34
May 08, 2018: Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update 36
Feb 14, 2018: Prothena Reports Fourth Quarter and Full Year 2017 Financial Results 38
Nov 07, 2017: Prothena Reports Third Quarter 2017 Financial Results and Provides R&D Update 40
Aug 08, 2017: Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update 42
May 09, 2017: Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update 44
Feb 14, 2017: Prothena Reports Fourth Quarter and Full Year 2016 Financial Results, and Provides Financial Guidance and R&D Update 46
Corporate Communications 48
Jun 25, 2018: Prothena Appoints Tran B. Nguyen As Chief Operating Officer 48
Feb 02, 2018: Prothena Announces Resignation of Sarah Noonberg As Chief Medical Officer 49
Jun 12, 2017: Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer 50
May 16, 2017: Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer 51
Clinical Trials 52
Jun 19, 2018: Prothena Announces Phase 1b Clinical Trial Results Of PRX002/RG7935 For Parkinson’s Disease Published In JAMA Neurology 52
Jun 18, 2018: New immunotherapy could stop progression of Parkinson’s disease 53
Sep 18, 2017: Prothena Presents New Research Supporting Clinical Relevance of Cardiac Biomarker NT-proBNP in AL Amyloidosis 54
Aug 15, 2017: Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting 56
Jul 05, 2017: Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson’s Disease 57
Jun 08, 2017: Anti-Alpha-Synuclein Antibody is a Potential Disease-Modifying Treatment for Parkinson’s Disease 58
Apr 02, 2017: Clinical Results Presented from Prothena’s Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s Disease 59
Mar 09, 2017: Results for Prothena’s Phase 1b Multiple Ascending Dose Study of PRX002/RG7935 in Patients with Parkinson’s Disease to be Presented at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases 61
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63

List of Tables
Prothena Corp Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Prothena Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Prothena Corp Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Prothena Corp Plc, Medical Devices Deals, 2012 to YTD 2018 10
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Prothena Biosciences Enters into R&D Agreement with Celgene Switzerland 12
MJFF Enters into Agreement with Prothena 14
Roche Enters Into Licensing Agreement With Prothena 15
Prothena Files Registration Statement for Public Offering of Shares 17
Prothena Raises USD155.3 Million in Public Offering of Shares 18
Prothena Raises USD137 Million in Public Offering of Shares 20
Prothena Raises USD122 Million in Public Offering of Shares 22
Prothena Completes Exercise of Underwriter's Over Allotment Option for Public Offering of Shares for USD123 Million 24
Prothena Raises USD82.7 Million in Public Offering of Shares 26
Prothena Completes Public Offering Of Shares For US$92 Million 28
Prothena Corp Plc, Key Competitors 30
Prothena Corp Plc, Key Employees 31
Prothena Corp Plc, Subsidiaries 32

List of Figures
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Prothena Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Prothena Corp Plc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Prothena Corp Plc (PRTA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Boralex Inc (BLX)-エネルギー分野:企業M&A・提携分析
    Summary Boralex Inc. (Boralex) is a renewable energy company that develops, constructs, and operates power plants. It produces electricity from wind, solar, hydro, natural gas, and wood residue sources; and sells that energy through long-term contracts. Boralex sources wood residues such as bark, wo …
  • Sihuan Pharmaceutical Holdings Group Ltd (460):製薬・医療:M&Aディール及び事業提携情報
    Summary Sihuan Pharmaceutical Holdings Group Ltd (Sihuan Pharmaceutical) is a pharmaceutical company that develops, manufactures and markets prescription drugs. The company offers products in the therapeutic areas of cardio-cerebral vascular system, central nervous system, metabolism, oncology and a …
  • Alkermes Plc (ALKS):企業の財務・戦略的SWOT分析
    Alkermes Plc (ALKS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • vTv Therapeutics Inc (VTVT):企業の財務・戦略的SWOT分析
    Summary vTv Therapeutics Inc (vTv), formerly TransTech Inc, is a pharmaceutical company that discovers, develops and commercializes human therapeutics. The company offers a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases includ …
  • Khatam al-Anbia:企業の戦略的SWOT分析
    Khatam al-Anbia - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Cajun Industries, LLC:企業の戦略的SWOT分析
    Cajun Industries, LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • ASC Pty Ltd:企業の戦略・SWOT・財務情報
    ASC Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary ASC Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Tessi S.A. (TES):企業の財務・戦略的SWOT分析
    Tessi S.A. (TES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Kentucky Power Co:発電所・企業SWOT分析
    Kentucky Power Co - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees ( …
  • Capita plc:企業の戦略・SWOT・財務情報
    Capita plc - Strategy, SWOT and Corporate Finance Report Summary Capita plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Shell Pakistan Ltd (SHEL):企業の財務・戦略的SWOT分析
    Summary Shell Pakistan Ltd (Shell Pakistan), a subsidiary of Royal Dutch Shell plc is an oil and gas company that markets petroleum products and compressed natural gas. The company operates through three segments such as retail, lubricants and aviation. It retail segment offers a range of fuels such …
  • Papyrus Australia Limited (PPY):企業の財務・戦略的SWOT分析
    Papyrus Australia Limited (PPY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Nordkraft AS:電力:M&Aディール及び事業提携情報
    Summary Nordkraft AS (Nordkraft) is an alternative energy company that offers renewable energy and related solutions. The company produces power and energy from magazine power, small hydro, and wind power, among others. It owns and operates power and energy generation plants magazine in the area of …
  • Samsung Life Insurance Co Ltd:企業の戦略・SWOT・財務情報
    Samsung Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Samsung Life Insurance Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • AstraZeneca Plc (AZN)-医療機器分野:企業M&A・提携分析
    Summary AstraZeneca plc (AstraZeneca) is a biopharmaceutical company that endeavors to discover, produce and commercialize a wide range of prescription drugs. It focuses on therapy areas such as respiratory; cardiovascular and metabolic disease (CVMD); and cancer, besides autoimmune, infection and n …
  • ContourGlobal LP-エネルギー分野:企業M&A・提携分析
    Summary ContourGlobal L.P. (CGLP) is an energy company that owns and operates of power generation assets. It develops, acquires and operates electric power and district heating businesses. The company develops and operates large central power plants in emerging markets to support the growth of the n …
  • FibroGen Inc (FGEN):製薬・医療:M&Aディール及び事業提携情報
    Summary FibroGen Inc (FibroGen) is a biotechnology company that discovers, develops and commercializes new therapeutics. The company’s pipeline product portfolio includes FG-4592, an oral small molecule inhibitor of HIF prolyl hydroxylases that is used for the treatment of anemia in chronic kidney d …
  • Parity Group plc (PTY):企業の財務・戦略的SWOT分析
    Summary Parity Group plc (Parity) is a technology company that offers professional recruitment, IT solutions and consultancy services. The company’s technology solutions include business intelligence, database analytics and development; IT consulting and application management support.The company pr …
  • Sanofi SA:戦略・SWOT・企業財務分析
    Sanofi SA - Strategy, SWOT and Corporate Finance Report Summary Sanofi SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Sykes Enterprises, Incorporated:企業の戦略・SWOT・財務情報
    Sykes Enterprises, Incorporated - Strategy, SWOT and Corporate Finance Report Summary Sykes Enterprises, Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆